Savonix picks up an extra $9.6M to bring its cognition test app to Asia

CONOR HALE | April 29, 2019

article image
Savonix has padded out its series A round with $9.6 million in extension financing, bringing its total haul up to $14.7 million to support the development of its mobile app that tests for signs of cognitive decline. Using machine learning and population health data, Savonix hopes to spot the early symptoms of diseases ranging from diabetes to dementia. The extra money will help the company expand its platform to markets in the U.S. and Asia, according to Savonix’s CEO and founder, Mylea Charvat. “The additional funding will also enable us to further develop and add additional features to our lead product Savonix Mobile, to better assess, track and monitor an individual’s cognitive health and to build personalized treatment plans to prevent and manage cognitive decline,” Charvat said in a

Spotlight

Canvax Biotech

For 16 years, Canvax has been an original manufacturer and supplier of the most innovative solutions, services, kits and R&D Reagents inside the Molecular Biology field. Thanks to our reliable, cost-effective and easy-to-use products, we enable our worldwide customers to improve its laboratory productivity and accelerate their discoveries.Based in Córdoba (Spain), since its foundation Canvax has focused on R&D of multiplex high throughput platforms (HTS) for Drug discovery and Diagnostic applied biosensors. Over a decade later, Canvax is a worldwide leading expert in Molecular Biology and GPCR expression in heterologous cells, with important patents and exclusive know-how.

OTHER ARTICLES
MEDICAL

Better Purification and Recovery in Bioprocessing

Article | August 2, 2021

In the downstream portion of any bioprocess, one must pick through the dross before one can seize the gold the biotherapeutic that the bioprocess was always meant to generate. Unfortunately, the dross is both voluminous and various. And the biotherapeutic gold, unlike real gold, is corruptible. That is, it can suffer structural damage and activity loss. When discarding the dross and collecting the gold, bioprocessors must be efficient and gentle. They must, to the extent possible, eliminate contaminants and organic debris while ensuring that biotherapeutics avoid aggregation-inducing stresses and retain their integrity during purification and recovery. Anything less compromises purity and reduces yield. To purify and recover biotherapeutics efficiently and gently, bioprocessors must avail themselves of the most appropriate tools and techniques. Here, we talk with several experts about which tools and techniques can help bioprocessors overcome persistent challenges. Some of these experts also touch on new approaches that can help bioprocessors address emerging challenges.

Read More
DIAGNOSTICS

Making Predictions by Digitizing Bioprocessing

Article | April 20, 2021

With advances in data analytics and machine learning, the move from descriptive and diagnostic analytics to predictive and prescriptive analytics and controls—allowing us to better forecast and understand what will happen and thus optimize process outcomes—is not only feasible but inevitable, according to Bonnie Shum, principal engineer, pharma technical innovation, technology & manufacturing sciences and technology at Genentech. “Well-trained artificial intelligence systems can help drive better decision making and how data is analyzed from drug discovery to process development and to manufacturing processes,” she says. Those advances, though, only really matter when they improve the lives of patients. That’s exactly what Shum expects. “The convergence of digital transformation and operational/processing changes will be critical for the facilities of the future and meeting the needs of our patients,” she continues. “Digital solutions may one day provide fully automated bioprocessing, eliminating manual intervention and enabling us to anticipate potential process deviations to prevent process failures, leading to real-time release and thus faster access for patients.” To turn Bioprocessing 4.0 into a production line for precision healthcare, real-time release and quickly manufacturing personalized medicines will be critical. Adding digitization and advanced analytics wherever possible will drive those improvements. In fact, many of these improvements, especially moving from descriptive to predictive bioprocessing, depend on more digitization.

Read More

Spotlight

Canvax Biotech

For 16 years, Canvax has been an original manufacturer and supplier of the most innovative solutions, services, kits and R&D Reagents inside the Molecular Biology field. Thanks to our reliable, cost-effective and easy-to-use products, we enable our worldwide customers to improve its laboratory productivity and accelerate their discoveries.Based in Córdoba (Spain), since its foundation Canvax has focused on R&D of multiplex high throughput platforms (HTS) for Drug discovery and Diagnostic applied biosensors. Over a decade later, Canvax is a worldwide leading expert in Molecular Biology and GPCR expression in heterologous cells, with important patents and exclusive know-how.

Events